Neuphoria Therapeutics (NEUP) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

NEUP · Stock Price

USD 5.34+0.33 (+6.59%)

Market Cap: $27.6M

Historical price data

Overview

Neuphoria Therapeutics is dedicated to developing transformative treatments for neuropsychiatric disorders, with a core focus on its lead clinical candidate, BNC210. The company has achieved key milestones, including positive Phase 2b results in PTSD and strategic partnerships with Merck and Carina Biotech, validating its platform. Its strategy centers on advancing BNC210 through late-stage trials for PTSD and broader anxiety indications while leveraging its ion channel targeting expertise to build a pipeline of next-generation CNS therapies.

PsychiatryNeurology

Technology Platform

Proprietary platform focused on designing small-molecule modulators of the α7 nicotinic acetylcholine receptor (α7 nAChR), including negative allosteric modulators (NAMs) for anxiety/stress and positive allosteric modulators (PAMs) for cognitive impairment.

Opportunities

The global market for PTSD and anxiety treatments represents a multi-billion dollar opportunity with high unmet need for rapid, non-sedating, non-addictive therapies.

BNC210's novel mechanism and positive Phase 2 data position it to capture significant share.

The partnership with Merck provides validation, non-dilutive funding, and potential future milestones.

Risk Factors

High clinical risk associated with advancing BNC210 into pivotal Phase 3 trials for PTSD.

Significant financing risk as a pre-revenue micro-cap company requiring substantial capital for late-stage development.

Intense competition in the CNS therapeutic landscape from both novel mechanisms and established treatments.

Competitive Landscape

Neuphoria competes in the novel anxiolytic space against companies targeting neurosteroids, glutamate, and other pathways. BNC210's key differentiator is its α7 NAM mechanism offering rapid efficacy without sedation or addiction risk, a profile aimed at displacing benzodiazepines and improving upon SSRIs. The Merck-partnered cognitive program enters the crowded but high-value Alzheimer's market.

More companies in Neuroscience & CNS →More companies in United States →